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150Objective: The objective of this study was to describe characteristics and early outcomes across a large multi-
center cohort undergoing coarctation or hypoplastic aortic arch repair.
Methods: Patients undergoing coarctation or hypoplastic aortic arch repair (2006-2010) as their first cardiovas-
cular operation in the Society of Thoracic Surgeons Congenital Heart Surgery Database were included. Group 1
patients consisted of those with coarctation or hypoplastic aortic arch without ventricular septal defect (coarc-
tation or hypoplastic aortic arch, isolated); group 2, coarctation or hypoplastic aortic arch with ventricular septal
defect (coarctation or hypoplastic aortic arch, ventricular septal defect); and group 3, coarctation or hypoplastic
aortic arch with other major cardiac diagnoses (coarctation or hypoplastic aortic arch, other).
Results:The cohort included 5025 patients (95 centers): group 1, 2705 (54%); group 2, 840 (17%); and group 3,
1480 (29%). Group 1 underwent coarctation or hypoplastic aortic arch repair at an older age than groups 2 and 3
(groups 1, 2, and 3, 75%, 99%, and 88%<1 year old, respectively; P<.0001). The most common operative
techniques for coarctation or hypoplastic aortic arch repair (group 1) were end-to-end (33%) or extended
end-to-end (56%) anastomosis. Overall mortality was 2.4%, and was 1%, 2.5%, and 4.8% for groups 1, 2,
and 3 respectively (P < .0001). Ventricular septal defect management strategies for group 2 patients
included ventricular septal defect closure (n ¼ 211, 25%), pulmonary artery band (n ¼ 89, 11%), or no inter-
vention (n ¼ 540, 64%) without significant difference in mortality (4%, 1%, 2%; P ¼ .15). Postoperative
complications occurred in 36% of patients overall and were more common in groups 2 and 3. There were no
occurrences of spinal cord injury (0/973).
Conclusions: In the current era, primary coarctation or hypoplastic aortic arch repair is performed predomi-
nantly in neonates and infants. Overall mortality is low, although those with concomitant defects are at risk
for higher morbidity and mortality. The risk of spinal cord injury is lower than previously reported. (J Thorac
Cardiovasc Surg 2013;145:150-8)The surgical management for coarctation of the aorta has
changed considerably since the first successful surgical re-
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The Journal of Thoracic and Cardiovascular Surgwas being extended to infants and, with the introduction of
prostaglandins in the mid 1970s, it became possible to
stabilize critically ill neonates and to offer surgical repair
of aortic coarctation for patients with complex disease.
Throughout the many decades since the first successful
surgery, techniques have included end-to-end resection and
anastomosis,1,2 subclavian flap aortoplasty,3 patch graft aor-
toplasty,4,5 and extended end-to-end repair.6-8 Indications
and techniques for performing repair through a sternotomy
have also been described,9 and this approach is now used
commonly when coarctation of the aorta is associated with
hypoplasia of the aortic arch.10
Prior to the availability of prostaglandins, patients receiv-
ing repair for aortic coarctation were often adolescents or
young adults whose disease was found on a routine physical
exam for sports or during a workup for hypertension. Chil-
dren and young adults undergoing coarctation repair occa-
sionally demonstrated some disturbing postoperative
complications.11 In 1972, Brewer and colleagues12 re-
viewed 12,532 coarctectomies and found 66 instances ofery c January 2013
Abbreviations and Acronyms
ASD ¼ atrial septal defect
C/HAA ¼ coarctation or hypoplastic aortic arch
CPB ¼ cardiopulmonary bypass
LHAC ¼ left heart aorta complex
PA ¼ pulmonary artery
PDA ¼ patent ductus arteriosus
PFO ¼ patent foramen ovale
STS ¼ Society of Thoracic Surgeons
STS-
CHSD
¼ Society of Thoracic Surgeons Congenital
Heart Surgery Database
VSD ¼ ventricular septal defect
Ungerleider et al Acquired Cardiovascular Disease
A
C
Dspinal cord injury, 51 of which were paraplegia, and the
commonly cited risk of paraplegia remains today at their de-
scribed incidence of 0.41%.
The outcomes and incidence of complications for coarc-
tation repair in our current surgical era have not been
investigated. The purpose of this study is to describe char-
acteristics and early outcomes across a large, multicenter,
contemporary cohort undergoing coarctation repair.METHODS
Data Source
The Society of Thoracic Surgeons Congenital Heart Surgery Database
(STS-CHSD) is the largest pediatric heart surgery registry worldwide
and currently contains information on>240,000 operations performed in
North America since 1998. It is estimated that the database currently rep-
resents>80% of all pediatric heart centers in the United States.13 Perioper-
ative, operative, and outcomes data are collected on all patients coded as
undergoing congenital and pediatric heart surgery at participating centers.
Data quality are evaluated through intrinsic data verification (eg, identifica-
tion and correction of missing/out-of-range value and inconsistencies in
values across fields), and a formal process of site visits and data audits.14
The Duke Clinical Research Institute serves as the data warehouse and an-
alytic center for all STS databases. This study was approved by the Duke
University institutional review board with waiver of informed consent
and by the Access and Publications Committee of the STS-CHSD.
Study Population
The study population included patients from any STS-participating cen-
ter undergoing coarctation or hypoplastic aortic arch (C/HAA) repair as
their first cardiovascular operation from 2006 to 2010 (patients with a his-
tory of previous cardiac surgery were excluded). We included both coarc-
tation repair and aortic arch repair in our review because we felt they both
addressed a spectrum of the same anatomic problem—important narrowing
of the thoracic aorta that required surgical intervention as an initial inter-
vention. Patients with missing data for key study variables were excluded.
Data Collection
Patient characteristics included age at surgery, gender, weight, cardiac
diagnoses, any noncardiac/genetic abnormalities, and any preoperative fac-
tors as defined by the STS-CHSD.15 Operative variables included use of
cardiopulmonary bypass (CPB; along with bypass time if applicable),
type of coarctation repair, and other procedures performed at the time
of C/HAA repair, including ventricular septal defect (VSD) closure orThe Journal of Thoracic and Capulmonary artery (PA) banding. Outcomes included in-hospital mortality,
postoperative length of stay, and postoperative complications as defined
in the STS-CHSD.15
Analysis
Patient characteristics, operative variables, and postoperative outcomes
were described using standard summary statistics. These variables were de-
scribed overall and then examined further for 3 main subgroups undergoing
C/HAA repair as described by Backer andMavroudis16 in the International
Congenital Heart Surgery Nomenclature and Database Project: group 1,
isolated C/HAA; group 2, C/HAA with a VSD; and group 3, C/HAA
with other cardiac diagnoses.
Group 1 patients with isolated C/HAA had no other cardiac defects
aside from secundum atrial septal defect (ASD), patent foramen ovale
(PFO), or patent ductus arteriosus (PDA) (C/HAA–isolated); group 2 pa-
tients with C/HAA also had a VSD but no other cardiac lesions other
than ASD, PFO, PDA (C/HAA–VSD); and group 3 patients with C/HAA
had complex intracardiac anatomy, including additional left-sided cardiac
lesions or other forms of complex heart disease (C/HAA–other).
Characteristics and outcomes in these 3 groups were compared using the
c2 test andKruskal-Wallis test. In addition, the C/HAA–VSDgroupwas sub-
divided further, and outcomes were evaluated for those undergoing VSD re-
pair at the time of C/HAA repair, those undergoing PA banding at the time of
C/HAA repair, and those with a diagnosis of VSD who did not undergo any
intervention at the time of C/HAA repair. Last, the C/HAA–other group was
also subdivided further into thosewith other left-sided lesions (mitral or aor-
tic valve disease, etc) versus those with other major cardiac diagnoses. All
analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary,
NC). A P value<.05 was considered statistically significant.RESULTS
Preoperative and Operative Variables
The overall cohort included 5025 patients undergoing
C/HAA repair from 95 centers, including 2705 (54%) in
group 1, 840 (17%) in group 2, and 1480 (29%) in group
3. Table 1 displays the preoperative characteristics of these
groups. Patients in the C/HAA–VSD group (group 2)
were more likely to undergo surgery as neonates or infants
(P<.0001). Patients in groups 2 and 3 had a significantly
higher likelihood of having a noncardiac or genetic abnor-
mality (P<.0001), and patients in either group 2 or group
3 were more likely to be acidotic, in shock, or require me-
chanical ventilation at the time of presentation (P<.0001).
Table 2 displays key operative variables for the overall
cohort and each of the subgroups. Cardiopulmonary bypass
was used more frequently during C/HAA repair for patients
in groups 2 (C/HAA–VSD) and 3 (C/HAA–other).Outcomes
Table 3 displays outcome variables for the overall cohort
and for each subgroup. The mortality data are also dis-
played graphically in Figure 1. In-hospital mortality was
1%, 2.5%, and 4.8% for groups 1, 2, and 3 respectively,
and was significantly higher in group 2 (P ¼ .001) and
group 3 (P<.0001) versus group 1.
Overall, 36% of patients had a postoperative complica-
tion of some type. The likelihood of any postoperative com-
plication was approximately twice as high for patients inrdiovascular Surgery c Volume 145, Number 1 151







group 3 P value
n 5025 2705 840 1480
Age at surgery, d
Median 19 32 12 14 <.0001
25% 7 9 6 7
75% 110 365 29 69
Age group, n (%) <.0001
Neonate, 0-30 d 2947 (59) 1343 (49.7) 643 (76.6) 961 (64.9)
Infant,>30 d-1 y 1210 (24) 685 (25.3) 187 (22.3) 338 (22.8)
Child,>1-12 y 697 (13.9) 553 (20.4) 9 (1) 135 (9.1)
Adolescent,>12-18 y 127 (2.5) 94 (3.5) 1 (0.1) 32 (2.2)
Adult,>18 y 42 (1) 29 (1) 0 (0) 13 (1)
Male/female, n 60/40 62/38 56/44 59/41 .01
Noncardiac/genetic abnormalities, n (%) 1072/4967 (21.3) 446/2675 (16.5) 169/832 (20.1) 457/1460 (30.9) <.0001
Any preoperative risk factor, n (%) 1580 (31) 656 (24) 346 (41) 578 (39) <.0001
Shock, n (%) 319 (6.4) 126 (4.7) 65 (7.7) 128 (8.7) <.0001
Acidosis, n (%) 227 (5.6) 82 (3.7) 49 (7.4) 96 (8.1) <.0001
Mechanical ventilation, n (%) 914 (18.2) 356 (13.2) 213 (25.4) 345 (23.3) <.0001
C/HAA, Coarctation or hypoplastic aortic arch; VSD, ventricular septal defect.
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the incidence of acidosis, cardiac arrest, chylothorax, un-
planned cardiac reoperation, and the need for prolonged
mechanical ventilator support was higher in groups 2 and
3. Group 3 patients had the highest likelihood of unplanned
readmission within 30 days. Of note was the absence of spi-
nal cord injury in any group for the 973 total operations per-
formed since the data field was added to the STS-CHSD in
2010.
Subgroup Analysis
Group 1. Of the 2705 patients in group 1 (C/HAA–iso-
lated), 2474 (91%) underwent coarctation repair as their pri-
mary procedure and 231 (9%) underwent aortic arch repair.
The STS-CHSD does not contain precise or strict anatomic
or physiologic criteria to guide coding of coarctation versus
aortic arch repair, and this choice is left to the discretion of
the surgeon or coding team. For the 2474 patients in group
1 coded as undergoing coarctation repair, the STS-CHSD
also specifies further the type of repair used. The vast major-
ity (89.1%) of these patients underwent end-to-end (or ex-
tended end-to-end) repairs. All other repair types accounted
for the remaining 10.9% of operations (Table 4). Of the
2474group1patients coded as undergoing coarctation repair,TABLE 2. Operative variables
Variable Overall C/HAA–isolated, group
n 5025 2705
PA band, yes; n (%) 288 (5.8) 0 (0)
CPB, yes; n (%) 1436 (28.6) 366 (13.5)
CPB time, min; mean  SD 117.9  59.3 98.6  62
C/HAA, Coarctation or hypoplastic aortic arch; VSD, ventricular septal defect; PA, pulmo
152 The Journal of Thoracic and Cardiovascular Surgin-hospital mortality was not significantly different for those
who underwent coarctation repair with the use of
CPB (2/156, 1.3%) versus without CPB (18/2318, 0.8%;
P¼ .5). For the231group1patients coded as undergoing aor-
tic arch repair, in-hospital mortality was also not statistically
different for those who underwent aortic arch repair with
CPB (5/210, 2%) versus without CPB (2/21, 10%; P ¼ .7).
Group 2. For the 840 patients who underwent C/HAA–
VSD, 540 (64%) were coded as undergoing coarctation re-
pair as their primary procedure and 300 (36%) were coded
as undergoing aortic arch repair. Ventricular septal defect
management fell into 1 of 3 strategies: (1) concurrent
VSD repair, (2) PA banding, and (3) no intervention for
the VSD. Table 5 displays patient outcomes separated by
each VSD management strategy. The majority of the pa-
tients did not have their VSD closed at the time of
C/HAA repair. In-hospital mortality is low and not statisti-
cally different for any strategy.
Groups 1 and 2. For the 3014 patients in groups 1 and 2
who were coded as having coarctation repair (as opposed
to aortic arch repair) as their primary procedure, 2474 did
not have a VSD (82%) and 540 (16%) had a VSD. For
the 531 patients whowere coded as having aortic arch repair
(as opposed to coarctation repair), 231 (44%) had no VSD1 C/HAA–VSD, group 2 C/HAA–other, group 3 P value
840 1480
89 (10.6) 199 (13.5) <.0001
494 (58.8) 576 (38.9) <.0001
127.4  53.6 121.7  59.6 <.0001
nary artery aortoplasty; CPB, cardiopulmonary bypass; SD, standard deviation.
ery c January 2013







group 3 P value
n 5025 2705 840 1480
In-hospital mortality, n/N (%) 119/5025 (2.4) 27/2705 (1) 21/840 (2.5) 71/1480 (4.8) <.0001
LOS, d; mean  SD (median) 14  22 (7) 9.7  16.2 (5) 19.7  24.3 (11) 18.6  27.6 (9) <.0001
Any complication, n/N (%) 1816/5025 (36) 666/2705 (24.6) 463/840 (55.1) 687/1480 (46.4) <.0001
Acidosis, n/N (%)* 81/4052 (2) 21/2206 (1) 12/663 (1.8) 48/1183 (4.1) <.0001
Cardiac arrest, n/N (%) 62/5025 (1.2) 11/2750 (0.4) 19/840 (2.3) 32/1480 (2.2) <.0001
Chylothorax, n/N (%) 165/5025 (3.3) 56/2705 (2.1) 35/840 (4.2) 74/1480 (5) <.0001
PERD, n/N (%) 98/5025 (2) 36/2705 (1.3) 25/840 (3) 37/1480 (2.5) .002
RLN injury, n/N (%) 176/5025 (3.5) 42/2705 (1.6) 76/840 (9) 58/1480 (3.9) <.0001
Phrenic nerve/paralyzed diaphragm 47/5025 (0.9) 10/2705 (0.4) 12/840 (1.4) 25/1480 (1.7) <.0001
Unplanned cardiac reoperation, n/N (%)y 33/973 (3.4) 7/479 (1.4) 9/177 (5.1) 17/297 (5.7) .002
Unplanned readmission within 30 d, n/N (%)y 36/973 (3.7) 12/499 (2.4) 5/177 (2.8) 19/297 (6.4) .01
Spinal cord injury, n/N (%)y 0/973 (0) 0/499 (0) 0/177 (0) 0/297 (0) NA
Mechanical ventilator support, n/N (%) 253/5025 (5) 64/2705 (2.4) 57/840 (6.8) 132/1480 (8.9) <.0001
All based on total group population, unless otherwise specified. C/HAA, Coarctation or hypoplastic aortic arch; VSD, ventricular septal defect; LOS, length of stay; SD, standard
deviation; PERD, pleural effusion requiring drainage; RLN, recurrent laryngeal nerve; NA, not applicable. *Some complications were only coded prior to 2010, and denominator
is specified. ySome complications were only coded since 2010, and denominator is specified.
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mortality was higher in those undergoing aortic arch repair
(7/231, 3%) versus those undergoing coarctation repair
(20/2474, 0.8%; P ¼ .001). A similar relationship was
seen in patients with a VSD; mortality was higher in those
undergoing aortic arch repair (12/300, 4%) compared with
those undergoing coarctation repair (9/540, 1.7%; P¼ .04).
However, these data should be interpreted with certain lim-
itations in mind, including the absence of precise anatomic
or physiologic criteria in the STS-CHSD to guide coding of
patients as either coarctation versus aortic arch repair, and
the lack of adjustment for potentially important hemody-
namic and/or anatomic variables not collected in the
STS-CHSD.
Group 3. For the 1480 patients in the C/HAA–other group,
546 (37%) had, primarily, defects of the left heart aortaFIGURE 1. Mortality for C/HAA–isolated (group 1), C/HAA–VSD
(group 2), and C/HAA–other major cardiac defects (group 3) compared
with the overall cohort of 5025 patients.C/HAA,Coarctation or hypoplastic
aortic arch; VSD, ventricular septal defect. *P¼ .001 compared with group
1. **P<.0001 compared with group 1.
The Journal of Thoracic and Cacomplex (LHAC), including Shone’s syndrome.17 These
defects included aortic stenosis (subvalvar, valvar, and
supravalvar) and mitral stenosis (subvalvar, valvar and
supravalvar), as well as a diagnosis of Shone’s syndrome.
The remaining 933 patients (63%) in this group had a vari-
ety of other complex cardiac diagnoses, including atrioven-
tricular septal defects (complete and partial), transposition
of the great arteries/VSD, single ventricle (heterotaxy, un-
balanced atrioventricular septal defects, double-inlet left
ventricle, tricuspid atresia), double-outlet right ventricle,
total anomalous pulmonary venous connection, and numer-
ous other anomalies. Table 6 displays characteristics and
outcomes for these 2 subsets. Patients in the LHAC sub-
group were less likely to have noncardiac/genetic abnor-
malities. The LHAC subgroup also had in-hospital
mortality that was significantly lower (8/546, 1.5%) than
the subgroup with other major cardiac diagnoses (63/534,
6.8%; P<.0001; Figure 2).DISCUSSION
This study reports the largest review of surgical repair for
C/HAA in the literature to date. Our review demonstrates
that patients who present in the current era for initialTABLE 4. Frequency of coarctation repair techniques for 2474
patients in group 1 coded as undergoing coarctation repair
Repair technique Frequency, n/N (%)
End-to-end anastomosis 820/2474 (33.1)
Extended end-to-end anastomosis 1385/2474 (56.0)
Subclavian flap repair 85/2474 (3.4)
Patch aortoplasty 104/2474 (4.2)
Interposition graft 70/2474 (2.8)
Other 10/2474 (0.4)
rdiovascular Surgery c Volume 145, Number 1 153
TABLE 5. VSD management strategy (group 2 patients)
Strategy n (%)
Patients in each repair
strategy<1 y old,%
CPB used for C/HAA
surgery, yes, n (%) Mortality, n (%)* LOS, d; median
VSD repaired 211 (25) 100 207 (98)y 9 (4) 13
PA band 89 (11) 99 23 (26) 1 (1) 13
No intervention for VSD 540 (64) 98 264 (49) 11 (2) 10
CPB, Cardiopulmonary bypass; C/HAA, coarctation or hypoplastic aortic arch; LOS, length of stay; VSD, ventricular septal defect; PA, pulmonary artery. *P ¼ .15 between
groups. yAlthough it would seem that 100% of patients undergoing VSD repair should have CPB, 4 patients did not. We do not know from the database whether this represents
a coding error or whether these patients had VSD closure off pump.
Acquired Cardiovascular Disease Ungerleider et al
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DC/HAA surgery are frequently young (often<1 year of age)
and can be critically ill (with a high likelihood of preoper-
ative risk factors, especially when the C/HAA is associated
with a VSD or other major cardiac diagnosis). Despite this,
in-hospital mortality is low, particularly when the C/HAA is
not associated with a VSD or other major cardiac defects.
Our study is also the first to report the incidence of
major postoperative complications from a large, multi-
institutional cohort.
Resection with end-to-end anastomosis, either without or
with extension, is by far the most commonly used technique
for repair of isolated coarctation (group 1 patients in our
study). Patch aortoplasty, either with a prosthetic patch or
a subclavian flap, is used less frequently, although pros-
thetic patch aortoplasty may be useful for older patients.18
Interposition grafts likely have limited, if any, role in neo-
natal or infant surgery and may be used more commonly
in older patients.
The use of CPB to repair isolated coarctation was not as-
sociated with significantly increased mortality risk in our
study.
Although our data illustrate that the preponderance of
patients who currently present for primary surgical repair
of C/HAA are young, 10% to 25% of C/HAA does present
during childhood or adolescence, particularly when the de-
fect is not associated with a VSD or with another major
cardiac defect. Because the STS-CHSD is a surgery-
based database, we do not know the number of patients
who receive catheter-based interventions (eg, angioplasty
or stenting) for coarctation treatment, but this likely has
an effect on the number of patients presenting for surgical
treatment in the older age groups. It may be possible to
learn more about overall treatment for disease (as opposed
to just surgical treatment for disease) and even aboutTABLE 6. Group 3 by subgroup (LHAC/Shone’s syndrome and other ma
Variable
Group 3 (C/HAA–other)
Overall, n (%) C
n 1480
Non Cardiac/Genetic Abnormality 457 (31)
PA band at time of coarctation repair 199 (13.5)
CPB, yes 576 (39)
Mortality 71 (4.8)
C/HAA, Coarctation or hypoplastic aortic arch; LHAC, left heart aorta complex; PA, pulm
154 The Journal of Thoracic and Cardiovascular Surglong-term outcomes by linking various databases to the
STS-CHSD.19
Unlike an earlier, single-institution report by Conte and
associates,10 the addition of a VSD to the diagnosis (group
2 patients in our study) increases significantly the mortality
risk of C/HAA repair by approximately 2 times. However,
this group of often-critically ill patients still has a very fa-
vorable prognosis with an overall low mortality rate. In
the group of patients with C/HAA–VSD, the management
strategy for the VSD did not seem to influence early out-
come significantly. However, each of these patients likely
had different anatomic and physiologic manifestations of
VSD, and the management strategies selected were likely
influenced by these factors as well as by institutional or in-
dividual surgeon preferences. Therefore, it is not possible to
claim from this review of the STS-CHSD that one strategy
is superior to another or, in fact, that they are all indeed
equal. There remains an important role for surgical experi-
ence and judgment in determining which strategy to use.
Quaegebeur and colleagues17 suggested that when a VSD
is present, PA banding is safer than 1-stage repair, but others
during a similar time frame,10 as well as more recent reports
in the literature, have challenged the validity and practical-
ity of this approach.20,21 Because the STS-CHSD only
tracks outcomes through hospitalization (and 30 days if
the patient is discharged prior to 30 days following surgery),
we do not know the mortality associated with the second
stage, as well as the interstage, for patients initially man-
aged with a PA band or even with deferred (eg, no) VSD in-
tervention. As a result, our analysis cannot compare the
ultimate outcome for VSD management strategies in pa-
tients with C/HAA. In their review published in 1995,
Conte and associates10 observed that 39% of VSDs
associated with coarctation closed spontaneously. Recentjor cardiac defects)
/HAA þ LHAC, n (%) C/HAA þ complex, n (%) P value
546 (37) 934 (63)
103 (19) 354 (38) <.0001
20 (3.7) 179 (19.2) <.0001
159 (29) 417 (45) <.0001
8 (1.5) 63 (6.8) <.0001
onary artery; CPB, cardiopulmonary bypass.
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FIGURE 2. Mortality for group 3 patients (C/HAA–other) separated
by whether they had C/HAA with LHAC (Shone’s syndrome; C/HAA þ
LHAC) defects versus C/HAA with other complex defects aside from
LHAC (C/HAA þ Complex Defects). C/HAA, Coarctation or hypoplastic
aortic arch; LHAC, left heart aorta complex. *P< .0001 compared with
C/HAA þ LHAC cohort.
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addition of unique patient identifiers and detailed documen-
tation of prior operations, will facilitate using the
STS-CHSD to perform this type of analysis in the future.
Recently reported outcomes for patients undergoing re-
pair of C/HAA have come primarily from single-
institution series, often intended to describe the virtues of
a certain surgical technique or repair strategy.8,20-26 Two
multi-institutional reviews have appeared in the cardiac sur-
gery literature during the past 18 years. In 1994, a Congen-
ital Heart Surgeon’s Society multi-institutional study was
reported by Quaegebeur and colleagues.17 They described
survival for 322 neonates with coarctation, 169 without,
and 153 with a VSD. Unlike our current study, they ex-
cluded from analysis 109 patients with other major cardiac
defects. Nonrisk-adjusted 1-month mortality was 7% and
was higher for patients with a VSD. Neonates with other
levels of LHAC obstruction had significantly higher mortal-
ity both at 1 month and at 24 months of follow-up. Survival
was also influenced negatively by the need to extend the co-
arctation repair proximal to the left common carotid artery,
regardless of the operative technique used. (Unfortunately,
the effect of this variable on outcome in our series could
not be evaluated from the data available in the STS-
CHSD). These outcomes were produced by Congenital
Heart Surgeon’s Society member institutions and are there-
fore likely to represent the best achievable outcomes for the
time.27 In 2008, Curzon and colleagues28 reviewed out-
comes in the STS-CHSD for 594 infants up to 90 days of
age at the time of surgery for C/HAA. Overall, the discharge
mortality was 3.5%. However, the discharge mortality for
low-weight infants was 7.1% compared with 2.7% for in-
fants with weight>2.5 kg and up to 4 kg at the time of re-
pair. Their study was not designed to evaluate the variables
in C/HAA repair (other than weight) that contribute toThe Journal of Thoracic and Caoutcome and was not intended to provide a comprehensive
analysis of C/HAA repair. In our current study, we have de-
vised subgroups of patients for analysis by important ana-
tomic distinctions such as the presence of a VSD or other
major cardiac anomalies, because these are common ac-
companying issues in planning surgical management for
C/HAA.
In our current study, we included patients whose
C/HAA existed in association with other major cardiac de-
fects so that the importance of having another major car-
diac defect in association with C/HAA could be better
understood in contrast to patients with more isolated dis-
ease of the aortic arch. Not surprisingly, when other major
cardiac defects (aside from or in addition to a VSD) are
associated with C/HAA, there is an increased risk for in-
hospital mortality and postoperative complications. Pa-
tients with C/HAA and obstructive defects of the LHAC
(Shone’s syndrome) have significantly lower in-hospital
mortality than patients with C/HAA and other major car-
diac diagnoses.
This article is the first to describe an expected incidence
of major postoperative complications from a large, multi-
institutional data set. The presence of chylothorax (and/or
pleural effusion requiring drainage) was low, but doubled
when coarctation repair was performed in patients with
VSDs or other major cardiac defects. Although the reported
incidence of recurrent laryngeal nerve injury ranges from
1.6% (C/HAA–isolated) to 9% (C/HAA–VSD), the true in-
cidence is likely higher because it is doubtful whether all
the patients reported to the STS-CHSD had a direct exami-
nation to assess vocal cord function, in the absence of post-
operative symptoms of aspiration or aphonia. Of particular
note is the high likelihood of unplanned hospital readmis-
sion for patients having C/HAA repair with associated other
cardiac diagnoses, suggesting that this is a group of patients
who would benefit from careful and timely postdischarge
surveillance.
The incidence of spinal cord injury is low—0% in this
series for 973 patients in the STS-CHSD since 2010 when
a data field for spinal cord injury was added. Spinal cord in-
jury has been reported in patients receiving coarctation sur-
gery who also have hyperthermia at the time of surgery,29 as
well as in patients with an aberrant right subclavian ar-
tery,30,31 but there were no patients in this large series
with confirmed spinal cord injury. This low incidence is
below the expected incidence of 0.41% (which would
predict 3 to 4 cases for this series) reported by Brewer
and colleagues,12 and suggests that the incidence, despite
anecdotal reports,31 is very low in the population of patients
who currently present for surgery. This low incidence, in
close to 1000 patients, also implies that a sample size
needed to demonstrate efficacy for techniques designed to
reduce the risk of this complication22,24,31 would need to
be much larger than what is generally produced byrdiovascular Surgery c Volume 145, Number 1 155
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strategies may not be able to be powered sufficiently to
address this issue. Further follow-up in the STS-CHSD
over several more years may provide a more accurate,
true incidence for this dreaded complication. From our re-
view, we can simply state that the modern-day incidence
of spinal cord injury following C/HAA repair is reassur-
ingly low.
We combined the patients coded for undergoing coarcta-
tion repair and hypoplastic aortic arch repair becausewe felt
that these 2 primary surgical procedures addressed a spec-
trum of the same entity—important narrowing of the aorta
(diffuse or discrete)—and could not be reasonably sepa-
rated because they were not adequately differentiated by
the current coding criteria of the STS-CHSD. Although
we caution that detailed analysis of aortic arch repair versus
coarctation repair is subject to ambiguity inherent to the
current STS-CHSD coding process, the data are still useful
because they represent how individual surgeons perceived
the repairs they were performing, and it will be important
to know how these data comparewithmore anatomically di-
rected coding in the future.
As in any review of STS-CHSD information, this study
has important limitations. We are aggregating what seem
to be similar patients but there is always the possibility of
coding errors or inclusion/exclusion errors inherent to our
categorizing. Nevertheless, the numbers are large enough
to remove any important deficiencies. It is believable that
a VSD adds to the risk and that other major cardiac defects
create an even higher-risk population. Although there are
individual reports that suggest high risk patients can receive
coarctation or arch repair with limited risk,8,23,26 the
numbers of patients in this review provide enough
‘‘power’’ to validate that while the risk of some additional
lesions (even a VSD) may be small, they still create
a significant effect on outcome. We would conclude that
risk is individual, but can be increased by small size,28 the
presence of a VSD, and other cardiac lesions (especially
if they are outside the spectrum of Shone’s syndrome, or
LHAC).
Study Limitations
Our review is time limited and lacks longer term patient
follow-up to enable conclusions to be tested against long-
term outcomes. We also cannot measure the recurrence
rate for coarctation and how it relates to surgical technique.
If the anatomy of a coarctation, or hypoplastic aortic arch,
has an influence on outcome, it is currently not definable
by the data in the STS-CHSD. In the future, we would rec-
ommend that the STS-CHSD incorporate anatomic descrip-
tors for coding coarctation repair versus aortic arch repair.
Extension of the repair proximal to the left common carotid
artery may be a good anatomic distinction between aortic
arch repair (repair extends proximal to left common carotid156 The Journal of Thoracic and Cardiovascular Surgartery) versus coarctation repair (repair can extend to, but
not proximal to, the left common carotid artery).10,17,32
This type of coding distinction can help us understand
further the results of our treatment for disease of the
aortic arch.
CONCLUSIONS
Coarctation, or hypoplastic aortic arch, is a surgical dis-
ease of neonates and infants, especially when it is associ-
ated with a VSD or other major cardiac defects. When
coarctation or hypoplastic aortic arch presents with only
a secundum ASD, PFO, or PDA, excellent surgical out-
comes can be expected. The use of CPB for coarctation re-
pair is not associated with a significantly increased
mortality risk. The presence of a VSD increases the risk
for in-hospital mortality from C/HAA repair. However,
the early survival for this group of patients is still excellent.
The presence of other major cardiac defects (in addition to
or aside from a VSD) along with C/HAA is associated with
significantly higher in-hospital mortality and postoperative
complications. The incidence of spinal cord injury was 0%
in this large series. Future enhancements to the STS-CHSD
coding criteria for coarctation and aortic arch repair can
help us evaluate our treatment strategies further for disease
of the aortic arch.
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Dr Gordon A Cohen (Seattle, Wash). Dr Ungerleider, I would
like to congratulate you and your coauthors for this excellent work
and I want to thank you, actually, for doing it because I think it is
a meaningful study in that nothing has been published with con-
temporary results on repair of aortic coarctation in quite awhile,
and so I really think that this adds to the literature.
I have a series of questions. I will break them into 4 general
themes and I will address all 4 themes now, but if you need me
to repeat any of them just let me know.The Journal of Thoracic and CaFirst, how does this information influence our practice moving
forward? Should we make any changes in how we practice and
should we make any changes in how we counsel families about
the surgical risk?
Second, what is the data quality, what are the limitations of the
data, and how are the data limited by combining coarctation and
hypoplastic aortic arch into a single group? Does this confuse
the message of your study?
Third, we often think of coarctation repair as a straightforward
operation with a short hospital stay. These data demonstrated
a 25% incidence of complication for coarctation and the hypoplas-
tic aortic arch group, and even higher for the other 2 with an
overall 36% incidence of complications. Should we be adjusting
our own expectations as well as those of the families for these op-
erations? How could we use this information to reduce complica-
tion rates?
And last, I was actually surprised to see the large percentage of
patients with these diagnoses who are being operated on outside of
the neonatal period. Can you speculate as to why? Interestingly, I
went to the database at Seattle Children’s since July 2006 and
looked up our own experience, because I thought it was different
than what we actually do, and in fact found almost identical num-
bers; so can you speculate as to why that is the case?
Dr Ungerleider. Thank you, Gordon, not only for your ques-
tions but for your friendship over the years.
You first question was: How is this going to influence our prac-
tice? I do not know whether it will influence our practice or
whether it should, but it certainly should help us understand our
practice. We have a lot of data now that are collected that can
give us information that we can relate to our families or to our col-
leagues about expectations. It also shows us a little bit about how
we want to modify the database in the future to answer questions
that we just simply cannot answer here, like recurrence rates or
what happens from VSD management strategies, so we have
some limitations with what we can say with the STS database
the way it is currently constructed.
You asked about data quality—Do we confuse the issue by in-
cluding hypoplastic aortic arch patients with coarctation pa-
tients?—and I hope we did not. We spent a lot of time thinking
about this and we just did not know how to separate patients hav-
ing aortic arch repair from patients having coarctation repair, be-
cause when patients have important narrowing of the aortic arch,
some people may call that an aortic arch repair and some people
a coarctation repair, and until we insert into the STS-CHSD some
kind of anatomic or physiologic descriptor that will guide the cod-
ing of arch repair versus coarctation repair—and we would rec-
ommend that perhaps that be repair that extends proximal to the
left common carotid artery—until we have that, we really cannot
separate those patients. We would like to analyze them. I can tell
you that when we looked at hypoplastic arch repair versus coarc-
tation repair, the incidence of mortality went up by about 1% for
each group. That is, 1% mortality increase from coarctation repair
to coarctation plus VSD, another 1% increase in mortality for hy-
poplastic arch repair, and then a 1% increase when VSD repair
was added to hypoplastic arch repair, but I cannot comment on
the quality of those data because we cannot specify how patients
are assigned (by their various surgical groups) to each particular
repair type.rdiovascular Surgery c Volume 145, Number 1 157
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operation and the incidence of complications. It can be a straight-
forward operation. As you see, only about half the patients in the
isolated group had complications. It can also be a very complex op-
eration, with a high likelihood of complication, so I think it is im-
portant to recognize that. The length of stay for isolated
coarctation was about 5 days as a median. It went up to about 11
days if there was a VSD and was about 9 days when coarctation
existed with other lesions, so it can be a complex convalescence.
Last, you asked about the incidence of neonates versus other pa-
tients. It is interesting that you went back to your database. I al-
ways say the memory is a poor database and so we may
remember that we are operating on a lot of neonates and infants,
and forget that there are other patients that are getting operated
on as well. The map is not the territory, meaning that our own in-
dividual experiences may not represent the overall totality of expe-
rience in the country, and that is a major benefit of the STS
database. I think the numbers here are pretty good and I would sug-
gest that what we are seeing is that about half the patients overall
being operated on for coarctation are neonates, that this percentage
of neonates is higher in the patients with more complex disease,
and that the incidence of complications after coarctation repair
is higher than we would initially remember. Thank you.
Dr Cohen. Thanks. One other quick comment. Thank you, by
the way, for giving me the paper in advance and allowing me to re-
view it, but one thing that was not clear to me from the paper and
even from the presentation: I am assuming that you excluded hy-
poplastic left heart syndrome from group 3. You did say that you158 The Journal of Thoracic and Cardiovascular Surgincluded single ventricles. It would be helpful, I think, both in
the manuscript and in the discussion to clarify that.
Dr Ungerleider. They were excluded. Hypoplastic left heart
syndrome is a separate disease. They get arch repairs, but they usu-
ally get something in addition.
Dr Tara Karamlou (San Francisco, Calif). Hi, Ross. Great pa-
per. I just had one quick comment and a question.
In terms of looking at complications like recurrent laryngeal
nerve injury, I think those things in this database are extremely
problematic because we do not really know the denominator. I
think we have to look at those data cautiously.
One of the things that struck me as curious was that there was
a much increased incidence of nerve injury when you had a con-
comitant VSD as opposed to other complex lesions. Do you
have a reason why you think that is the case or do you think it is
just an anomaly of the data?
Dr Ungerleider. Clearly, the incidence of recurrent laryngeal
nerve would probably be very different if it were looked for in
all patients. All patients would have to receive some form of di-
rect exam, and I think that the STS database information in this
study only represents those patients who had aphonia or aspira-
tion or a reason to be coded as recurrent laryngeal nerve injury.
We can use these kinds of data to guide our questions for the fu-
ture, and so if we really want to know more about why there
seems to be a higher incidence of recurrent laryngeal nerve injury
in certain subgroups of patients, we need to construct the data-
base to help us answer those questions in the future. Thank
you all.ery c January 2013
